From:  Therapeutic role of probiotics in motor and non-motor symptoms of Parkinson’s disease

 Experimental studies showing depression and anxiety symptoms improvement induced by probiotic interventions in PD.

Study (year)Probiotic(s)DurationDose/PresentationOutcome
Human studies
Sun et al. (2022) [82]Probio-M8 (Bifidobacterium animalis subsp. lactis)3 months2 g of Probio-M8 powder (3 × 1010 CFU/day; maltodextrin as excipient) dailyDepression (HAMD-17): significant improvement vs. control (p < 0.001). Anxiety (HAMA): significant improvement vs. control (p < 0.001).
Yang et al. (2023) [92]Lacticaseibacillus paracasei strain Shirota (LcS)12 weeksFermented milk drink containing 1 × 1011 CFU of LcS, once dailyDepression (HAMD-17): significant improvement vs. control (p = 0.010). Anxiety (HAMA): significant improvement vs. control (p = 0.005).
Zeng et al. (2024) [93]Bacteroides fragilis BF839 + earthworm protein12 weeks10 g supplement dissolved in 200 mL water, twice daily (each 10 g containing 106 BF839 and 0.3 g earthworm protein)Depression: significant reduction in HAMD-24 score (−3.91 ± 3.99 vs. +1.15 ± 3.42, p < 0.001). Anxiety: significant reduction in SAS score (−7.04 ± 5.71 vs. −1.23 ± 2.34, p < 0.001). Both improvements sustained through 12 weeks compared to placebo.

PD: Parkinson’s disease; HAMD-17: Hamilton Depression Rating Scale 17; HAMA: Hamilton Anxiety Rating Scale; SAS: Self-Rating Anxiety Scale.